Fotivda (Tivozanib HCl) Patent Expiration, LOE Window & CMS Spending

Fotivda (Tivozanib HCl) by Aveo: FDA Orange Book core substance LOE 2028-11-16 (last listed 2039-11-05), 0 AB generics, $126.1M 2024 CMS Part D & Medicaid spend, and 6 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorAveo
FDA Application & PathwayN212904 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE Date2028-11-16
Last Listed Patent or Exclusivity Date2039-11-05
Orange Book Patents (*PED Extensions)2 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$126.1M
2024 Medicare Part D Spend$118.9M
2024 Medicaid Spend$7.2M
Reported Wholesale Price Change (CA SB 17)6 WAC filings (max 25.4% 2-yr change)